EdRIP et al. in CHF 25m GenKyoTex series-C extension

The fresh capital came as an extension to the €14.5m series-C round provided by the same investors in May 2011.

The proceeds will be used to fund phase II clinical testing of GenKyoTex's lead compound, NOX inhibitor GKT137831, for the treatment of diabetic nephropathy.

Company
GenKyoTex is a biopharmaceutical company headquartered in Geneva. It was founded in 2006 and focuses on the discovery and development of drugs targeting a family of enzymes called NADPH oxidases (NOX).

GenKyoTex's products are designed to be used in the treatment of conditions including diabetic hypertension, myocardial infarction, Alzheimer's disease and Parkinson's disease.

People
Gilles Nobécourt led the deal for EdRIP. Eric Meldrum joined the company as chief scientific officer.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Andera Partners
• Switzerland